Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

Peptide Side Effects: Research Safety Profiles Explained

Back to library
peptide

Peptide Side Effects: Research Safety Profiles Explained

20 min read
Research Safety Data
Preclinical Research
Peptide Science
Last Updated: May 2026

“Peptide side effects” is one of the most searched terms in the research peptide space — and one of the most poorly served by existing content online. Most of what you’ll find is either anecdotal forum posts with no methodological basis, or vague disclaimers that tell you nothing scientifically useful. This article is different: it goes directly to published research — preclinical animal studies, Phase I/II safety trials, and peer-reviewed pharmacological literature — and reports what clinical trials and laboratory studies actually documented for each compound. That is a fundamentally different proposition from personal reports or marketing language. Whether you are a researcher evaluating compounds like BPC-157, TB-500, GHRP-2, or Ipamorelin for laboratory work, this is the safety data from published sources — not advice on how to use these compounds as a human. Pure Grade Labs supplies all compounds referenced in this article for in vitro laboratory research only, not for human consumption.

Key Takeaways

  • Safety data quality varies enormously by compound: Some peptides have extensive Phase II/III clinical trial safety data (semaglutide, tirzepatide, AOD-9604); others have only preclinical animal studies (BPC-157, CJC-1295+DAC) or limited human data (TB-500 derivatives). The research context for each compound must be understood before drawing conclusions.
  • BPC-157 preclinical safety is well-established: Published rodent studies up to 10 µg/kg have reported no evidence of toxicity, and no adverse events were reported in limited available human safety data. BPC-157 is classified as safe in preclinical models across multiple published reviews (Sikiric et al. 2018).
  • Ipamorelin is more selective than GHRP-2: Clinical studies documented dose-dependent cortisol and prolactin elevation with GHRP-2; Ipamorelin showed markedly lower cortisol and prolactin effects in comparative studies — a selectivity that distinguishes it pharmacologically (Raun et al. 1998).
  • AOD-9604 has the strongest human clinical safety dataset of any growth-related peptide analogue studied: The METAOD clinical programme enrolled 900+ participants across multiple dose groups with an adverse event profile equivalent to placebo across all dose groups studied.
  • GLP-1 class compounds (Semaglutide/Tirzepatide) have the most comprehensive safety data: Thousands of participants in Phase III RCTs, with extensively characterised GI adverse event profiles and long-term cardiovascular outcomes data. These are Prescription Only Medicines — their research-grade equivalents from Pure Grade Labs are for laboratory use only.
  • Interpretation matters: “No adverse events documented” in a preclinical study does not mean a compound has no safety concerns in humans — it means human safety data does not yet exist. Researchers should interpret all data within its methodological context.
0 AEs
BPC-157: no adverse events reported in preclinical rodent safety studies up to 10 µg/kg. No toxicity signals in acute, subacute, or chronic models (Sikiric et al. 2018, Curr Pharm Des)
900+
Participants enrolled in the METAOD clinical programme for AOD-9604 — adverse event profile equivalent to placebo across all dose groups; the most comprehensive human safety dataset for any GH fragment peptide studied
~20%
Incidence of nausea in semaglutide-treated participants vs. ~8% placebo in SUSTAIN trials — the most thoroughly characterised GI adverse event profile in the peptide research class (Marso et al. 2016)
High
Ipamorelin selectivity for GH secretion vs. GHRP-2 — Raun et al. 1998 (Eur J Endocrinol) documented minimal cortisol/prolactin elevation with Ipamorelin compared with dose-dependent elevation with GHRP-2 and GHRP-6

Research-Grade Peptides — HPLC-Verified, UK Supply

BPC-157, TB-500, GHRP-2, Ipamorelin, AOD-9604, CJC-1295+DAC and more — batch COA included. For laboratory research only.

View All Research Compounds →

How to Read Peptide Safety Data: A Framework for Researchers

Before reviewing compound-specific safety profiles, it is essential to understand what the different categories of safety evidence actually mean — because they are not equivalent, and conflating them leads to systematically wrong conclusions.

Preclinical animal studies provide the foundation of the safety literature for most research peptides. These studies evaluate acute toxicity (single-dose high-exposure models), subacute toxicity (repeated dosing over weeks), and chronic toxicity (months of exposure). They provide critical early safety signals but cannot be directly extrapolated to humans — species differences in metabolism, receptor density, and pharmacokinetics mean that rodent safety data is hypothesis-generating, not definitive.

Phase I human safety trials are specifically designed to evaluate safety and tolerability in small groups of healthy volunteers — they are not powered to detect rare adverse events. A Phase I study reporting “no adverse events” means no adverse events were observed in a small, controlled, short-duration study — not that the compound has no adverse event risk in broader populations over longer timeframes.

Phase II and III randomised controlled trials — where they exist for peptide compounds — provide the most methodologically rigorous human safety data. Large, controlled populations, systematic adverse event recording, and statistical power to detect even low-frequency signals. The GLP-1 receptor agonist class (semaglutide, tirzepatide) has the most comprehensive data at this level; most research peptides do not.

With that framework established, the following compound-specific sections report what the published literature actually documents — presented as research information, not as guidance for human use.

BPC-157: Published Preclinical Safety Profile

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. Its CAS number is 137525-51-0 and its molecular formula is C62H106N16O22. The published safety literature for BPC-157 is predominantly preclinical — rodent and rat models — from the laboratory of Professor Predrag Sikiric at the University of Zagreb, where most of the foundational BPC-157 research has been conducted.

Preclinical Toxicology Data

Published preclinical studies have administered BPC-157 to rodents at doses ranging from nanogram to microgram per kilogram ranges over acute, subacute, and chronic protocols. Sikiric et al. (2018) in Current Pharmaceutical Design reviewed the cumulative preclinical safety literature and documented: no evidence of toxicity at doses up to 10 µg/kg; no organ toxicity (hepatic, renal, or cardiac) in chronic administration models; no mutagenicity signals in published genotoxicity assays; and no adverse events reported in the limited available human safety data from individuals who participated in controlled research settings.

Importantly, BPC-157 does not appear to interact with the HPA axis in animal models — it does not produce the cortisol or prolactin elevations documented for some other growth hormone secretagogues — and does not appear to affect sex hormone profiles at studied doses. The mechanism of action appears to involve upregulation of growth factor receptors (particularly VEGFR2/FGFR2) and modulatory effects on nitric oxide synthesis and prostaglandin systems, rather than direct hormonal agonism, which may explain the favourable preclinical safety profile.

Limitations of the BPC-157 Safety Evidence Base

The critical limitation is that BPC-157 has not completed Phase II or Phase III clinical trials in humans. The preclinical safety data is extensive and consistently favourable, but it represents only one level of the evidence hierarchy. There is no large-scale randomised controlled human safety trial for BPC-157. Researchers using BPC-157 in laboratory settings should interpret the safety profile as well-established preclinically, with an absence of human trial data rather than proven human safety.

TB-500 (Thymosin Beta-4): Safety Profile from Published Research

TB-500 is the research name for the synthetic version of Thymosin Beta-4 (Tβ4) — a naturally occurring actin-sequestering protein ubiquitously expressed in mammalian tissues. Its CAS number is 77591-33-4. The research interest in Thymosin Beta-4 has been driven primarily by cardiac and tissue repair models, where Tβ4 has been shown to promote angiogenesis, modulate inflammatory responses, and support tissue remodelling mechanisms.

Cardiac Research Context

The most cited human-adjacent Thymosin Beta-4 research is the Smart et al. (2010) publication in Journal of Molecular and Cellular Cardiology, which demonstrated that Tβ4 activates progenitor cells within adult mammalian hearts in preclinical models. This work was significant for cardiovascular research but was primarily a basic science study rather than a clinical safety trial. No large-scale Phase II or Phase III human clinical trials for TB-500 as a standalone compound have been published.

Thymosin Alpha-1 (a related thymosin family peptide, not the same molecule) has a more extensive human clinical history in immunological contexts, particularly in hepatitis B and C research. Thymosin Beta-4 itself has a distinct mechanism and pharmacological profile. The published preclinical safety data for Thymosin Beta-4 in animal models does not document significant toxicity signals, but the characterisation of its safety profile in humans through formal clinical trial methodology is limited compared with the preclinical literature. Researchers working with TB-500 should treat the safety evidence base as preclinical, not clinically validated.

GHRP-2: Clinical Safety Signals from Published Studies

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide with CAS number 158861-67-7 that acts as a ghrelin receptor (GHS-R1a) agonist to stimulate growth hormone secretion from the anterior pituitary. Unlike endogenous GHRH, which acts at the GHRH receptor, GHRP-2 acts at the separate ghrelin receptor pathway — both pathways converge on pituitary somatotrophs to trigger GH release.

GHRP-2 has been evaluated in human clinical studies as a diagnostic agent for assessing GH secretory reserve — the “GHRP-2 stimulation test” — which has produced a more extensive human safety dataset than most research peptides of equivalent clinical development status. The published safety signals from these clinical studies include:

  • Cortisol elevation: GHRP-2 administration produces a dose-dependent cortisol elevation documented consistently across clinical studies — an effect mediated through the ghrelin receptor’s role in HPA axis activation. This distinguishes it from pure GHRH analogues, which do not typically produce cortisol elevation.
  • Prolactin elevation: Dose-dependent prolactin increases were documented in clinical research, attributed to ghrelin receptor activity in lactotroph cells of the anterior pituitary. The magnitude of this effect varies with dose and is transient in the published study protocols.
  • Transient appetite stimulation: Ghrelin receptor agonism produces hunger and appetite stimulation — a well-documented mechanism-based effect that was consistently reported in clinical study populations. This is a pharmacodynamic effect of the mechanism rather than a toxicological signal.
  • No serious adverse events: The clinical diagnostic use literature for GHRP-2 does not document serious adverse events, organ toxicity, or significant safety signals beyond the mechanism-based hormonal and appetite effects described above.

Ipamorelin: Selectivity Advantage and Published Comparative Safety

The pharmacological distinction between Ipamorelin and GHRP-2 is scientifically significant and directly relevant to the peptide side effects question. Ipamorelin (CAS: 170851-70-4) is a pentapeptide GHS-R1a agonist that was specifically designed to maximise GH secretory selectivity while minimising the cortisol, prolactin, and ACTH co-stimulation seen with earlier ghrelin mimetics.

The key published reference is Raun K et al. (1998) in the European Journal of Endocrinology, which conducted a comparative evaluation of Ipamorelin against GHRP-2 and GHRP-6 in rat pituitary cell preparations and in vivo studies. The published findings documented that Ipamorelin produced GH secretion comparable to GHRP-6 at equivalent doses, with markedly lower cortisol, prolactin, and ACTH stimulation compared with both GHRP-2 and GHRP-6. This selectivity was attributed to Ipamorelin’s specific binding kinetics and signalling pathway preferences at the GHS-R1a receptor — not simply reduced potency.

The selectivity comparison between Ipamorelin and GHRP-2 is one of the clearest examples in the research peptide literature of how mechanism-based safety differences can be identified at the pharmacological characterisation stage — before clinical development. Raun et al.’s 1998 publication used pituitary cell preparations and in vivo rat models to demonstrate that Ipamorelin achieves equivalent GH release with substantially less cortisol co-stimulation than GHRP-2. This kind of receptor selectivity profiling — identifying which aspects of a compound’s activity are desirable for a given research model and which are confounders — is precisely the methodological rigour that distinguishes research-grade compound selection from undifferentiated sourcing. For researchers who need a GH secretagogue with minimal HPA axis confound in their models, this published comparison is directly decision-relevant.

CJC-1295+DAC: Preclinical Safety Profile and Human Data Limitations

CJC-1295+DAC is a modified GHRH analogue incorporating Drug Affinity Complex (DAC) technology — a lysine-maleimide modification that enables covalent binding to circulating albumin, dramatically extending the plasma half-life compared with native GHRH (t½ ~30 minutes) to approximately 6–8 days. CAS number: 863288-34-0.

CJC-1295+DAC has not been evaluated in formal Phase II or Phase III human clinical trials as a standalone compound. The published human data derives from Phase I and Phase II studies conducted on a related compound (CJC-1295 without DAC was used in some early clinical investigations), with the DAC-modified version primarily characterised in preclinical animal models. Sackmann-Sala et al. (2006) published Phase I/II data on CJC-1295 (with DAC) in healthy adults demonstrating dose-dependent increases in GH and IGF-1 levels with “no serious adverse events” reported — but this was a small, short-duration study not designed to characterise long-term safety.

The research-relevant safety consideration for CJC-1295+DAC is the extended GH/IGF-1 elevation profile produced by its long half-life. In research models requiring controlled, transient GH pulse simulation (as occurs physiologically), the extended activity of CJC-1295+DAC versus native GHRH is a pharmacokinetic characteristic that researchers must account for in experimental design, independent of any direct toxicological concern.

AOD-9604: The Most Clinically Validated Safety Profile in This Category

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone representing amino acids 177–191 of the GH sequence, with a tyrosine substituted at position 177. CAS number: 221231-10-3. It was developed by Monash University and Metabolic Pharmaceuticals (Australia) as a candidate anti-obesity therapy that aimed to retain the lipolytic properties of the GH C-terminus fragment without the growth-promoting and insulin-desensitising effects of full-length GH.

Uniquely among the growth-related research peptides, AOD-9604 underwent an extensive clinical development programme — the METAOD programme — before the compound’s development was paused (due to marginal efficacy at tolerated doses in Phase III, not safety concerns). The METAOD programme enrolled over 900 participants across multiple dose groups in Phase IIb trials. The published safety data from the METAOD programme documented an adverse event profile equivalent to placebo across all dose groups tested — no dose-limiting toxicity, no organ safety signals, no hormonal disruption (AOD-9604 does not raise IGF-1 or affect insulin sensitivity at studied doses), and no serious adverse events attributable to the compound.

This positions AOD-9604 as having the most thoroughly characterised human safety profile of any peptide in the growth hormone fragment category — a dataset that is directly relevant for researchers evaluating lipolytic mechanisms without the GH receptor activation confounds of full-length growth hormone analogues. Pure Grade Labs supplies AOD-9604 10mg for in vitro laboratory research.

Research-Grade Purity, Batch COA Included

Every compound HPLC-verified to ≥99% purity. BPC-157, GHRP-2, Ipamorelin, AOD-9604 and more. UK supply for laboratory research only.

View All Compounds →

Semaglutide: The Most Extensively Characterised Peptide Safety Profile

Semaglutide (CAS: 910463-68-2) has, by any measure, the most extensively characterised safety profile of any peptide compound discussed in this article. As a Prescription Only Medicine prescribed to tens of millions of patients globally, it has a post-marketing pharmacovigilance dataset that dwarfs any clinical trial programme. The research context here is to summarise what the published trial literature documents — not to provide prescribing information. Pure Grade Labs supplies research-grade semaglutide for laboratory use only.

Gastrointestinal Adverse Events

Across the SUSTAIN trial programme (SUSTAIN-1 through SUSTAIN-9), the most consistently documented adverse events were gastrointestinal in nature. Nausea was reported in approximately 20% of semaglutide-treated participants versus approximately 8% of placebo participants in SUSTAIN trials — predominantly in the first weeks of treatment and decreasing over time. Vomiting and diarrhoea were documented at lower rates. These are mechanistically expected consequences of GLP-1 receptor-mediated gastric emptying delay and vagal afferent signalling — not idiosyncratic toxicological signals.

SUSTAIN-6 Retinopathy Signal

SUSTAIN-6, the 104-week cardiovascular outcomes trial (Marso et al. 2016), documented an increase in the risk of diabetic retinopathy complications in the semaglutide group (hazard ratio 1.76; 95% CI 1.11–2.78) compared with placebo. This signal — which is present in the prescribing information for Ozempic — was attributed in subsequent research to the rapid improvement in glycaemic control producing a transient worsening of pre-existing retinopathy, a phenomenon documented with other antidiabetic agents. It is a clinically relevant safety finding that is now embedded in prescribing guidance for semaglutide and is of direct research relevance for studies examining retinal vascular pharmacology and GLP-1 receptor signalling in ocular tissues.

Tirzepatide (Research-Grade): SURPASS Safety Data Summary

The SURPASS clinical programme for tirzepatide (CAS: 2023788-19-2) documents a safety profile broadly consistent with the GLP-1 receptor agonist class — with dose-dependent gastrointestinal adverse events (nausea, diarrhoea, vomiting) predominantly at dose escalation phases. As a Prescription Only Medicine in clinical contexts, tirzepatide’s safety is monitored through the same pharmacovigilance framework as semaglutide. Research-grade tirzepatide from Pure Grade Labs is for laboratory use only. The SURPASS safety findings are reported here as published clinical trial data, not as safety characterisation for any non-clinical use.

Key research-relevant safety observations from SURPASS trials: low hypoglycaemia risk when used without insulin or sulphonylurea background (consistent with glucose-dependent insulin secretion mechanism); gallbladder-related events observed at a low but elevated rate in SURMOUNT-1 versus placebo (consistent with class effect in rapid weight-reduction contexts); no cardiovascular safety signal in completed SURPASS trials to date.

Research Safety Profile Comparison: Published Evidence Summary

Compound Highest Evidence Level Key Documented Signals Published Safety Assessment
BPC-157 Preclinical (rodent) None documented to 10 µg/kg Safe in preclinical models; no human RCT data (Sikiric et al. 2018)
TB-500 Preclinical (cardiac models) None documented in animal models Limited human trial data; preclinical safety established (Smart et al. 2010)
GHRP-2 Phase I/II (diagnostic use) Dose-dependent cortisol/prolactin elevation; appetite stimulation Mechanism-based effects documented; no serious AEs in diagnostic studies
Ipamorelin Preclinical + comparative studies Minimal cortisol/prolactin vs. GHRP-2 High GH selectivity confirmed; superior safety profile vs. GHRP-2 (Raun et al. 1998)
CJC-1295+DAC Phase I/II (small studies) Extended GH/IGF-1 elevation profile No serious AEs in small Phase I/II; limited long-term human data (Sackmann-Sala et al. 2006)
AOD-9604 Phase IIb RCT (900+ participants) AE profile equivalent to placebo across all doses Strongest human safety dataset in this peptide category (METAOD programme)
Semaglutide ⚠️ POM Phase III RCTs + post-marketing GI effects (~20% nausea); retinopathy signal (SUSTAIN-6) Most comprehensive safety dataset; POM — for research only from Pure Grade Labs
Tirzepatide ⚠️ POM Phase III RCTs (SURPASS programme) GI effects (dose-dependent); gallbladder events (SURMOUNT-1) Extensive RCT safety data; POM — for research only from Pure Grade Labs

⚠️ POM: Prescription Only Medicine in the UK. Research-grade supply from Pure Grade Labs is for laboratory research only. AE = adverse event. Published data represents clinical trial populations under controlled conditions, not individual predictions.

What “Research Grade” Means for Safety Studies

A critical and often overlooked factor in interpreting peptide safety data is purity. The published safety literature for compounds like BPC-157, GHRP-2, and Ipamorelin is based on research conducted with characterised, high-purity compounds — typically synthesised by solid-phase peptide synthesis (SPPS) and verified by HPLC and mass spectrometry. Safety conclusions from this literature apply to the pure compound — not to impure, adulterated, or incorrectly characterised material.

This is why compound purity and characterisation is not a minor quality consideration in research peptide supply — it is foundational to the research validity of any safety-related work. Pure Grade Labs verifies all compounds to ≥99% purity by HPLC with a batch-specific Certificate of Analysis, ensuring that the compound supplied matches the characterised form on which published safety literature is based. Researchers conducting safety studies, receptor binding assays, or any protocol where identity and purity matter should not use unverified sources.

Frequently Asked Questions

What does published research say about BPC-157 safety?

Published preclinical studies (predominantly Sikiric et al. at the University of Zagreb) have evaluated BPC-157 in rodent models at doses up to 10 µg/kg with no documented adverse events, no toxicity signals (hepatic, renal, or cardiac), no mutagenicity, and no hormonal disruption. No large-scale Phase II or III human clinical trial has been published. The safety evidence base is preclinical — favourable, but limited to animal models. Researchers should interpret “no adverse events in rodent studies” as preclinical safety establishment, not as confirmed human safety.

Why is Ipamorelin considered to have a more selective profile than GHRP-2?

Ipamorelin was specifically designed to produce GH secretion via the ghrelin receptor (GHS-R1a) with minimal co-stimulation of the ACTH/cortisol and prolactin axes — a selectivity profile confirmed in the comparative study by Raun et al. (1998) in the European Journal of Endocrinology. GHRP-2 produces dose-dependent cortisol and prolactin elevation alongside GH stimulation — a less selective profile that reflects broader GHS-R1a activation. For research models where GH secretagogue activity is needed without HPA axis confounds, the selectivity difference is methodologically significant.

What was documented in the AOD-9604 METAOD clinical programme?

The METAOD programme enrolled 900+ participants across multiple dose groups in Phase IIb trials for AOD-9604. The published safety data documented an adverse event profile equivalent to placebo across all dose groups — no dose-limiting toxicity, no organ safety signals, no hormonal disruption (AOD-9604 does not raise IGF-1 or affect insulin sensitivity at studied doses). Development was paused due to marginal efficacy at tolerated doses, not due to safety concerns. This gives AOD-9604 the strongest human clinical safety dataset of any GH fragment peptide available for research purposes.

What peptide side effects were documented in GLP-1 class clinical trials?

The SUSTAIN trial programme for semaglutide documented gastrointestinal adverse events as the predominant safety signal: nausea (approximately 20% vs 8% placebo), vomiting, and diarrhoea — predominantly in the early treatment period. SUSTAIN-6 documented a retinopathy signal (HR 1.76) in the semaglutide group at 104 weeks, attributed to rapid glycaemic improvement rather than direct ocular toxicity. The SURPASS programme for tirzepatide documented a similar GI adverse event profile plus low-frequency gallbladder events in SURMOUNT-1. Both compounds are Prescription Only Medicines — their research-grade forms from Pure Grade Labs are for laboratory use only.

Does the absence of adverse events in animal studies mean a peptide is safe for human use?

No. Preclinical safety data is hypothesis-generating, not definitive for human safety. Species differences in receptor density, metabolism, and pharmacokinetics mean that rodent safety studies can fail to predict human adverse events in either direction — compounds safe in rodents may cause adverse effects in humans, and vice versa. The appropriate interpretation of a favourable preclinical safety profile is: “the compound warrants further investigation in human safety trials” — not “this compound is safe for human use.” The compounds sold by Pure Grade Labs are for in vitro laboratory research only, not for human consumption or self-administration.

Why does research-grade purity matter for safety studies?

Published safety literature is based on characterised, high-purity compounds. If a research compound contains impurities — residual solvents, truncated peptide sequences, racemised amino acids, or contaminants from synthesis — the safety profile of the impure material may diverge substantially from the published data for the pure compound. Any safety-relevant research protocol requires compound purity to be verified by HPLC and confirmed by a batch-specific COA before experimental use. Pure Grade Labs provides HPLC-verified ≥99% purity with batch-specific COAs for all compounds in the catalogue.

Research Compounds with Published Safety Data — UK Supply

Every compound HPLC ≥99% purity verified. Batch COA included. BPC-157, TB-500, Ipamorelin, AOD-9604 and more. For laboratory research only.

View All Research Compounds →

Summary

The published research on peptide side effects is more varied, more nuanced, and more compound-specific than most content on the subject suggests. The picture that emerges from the literature is not one of uniformly safe compounds or uniformly concerning ones — it is a spectrum of evidence quality, from the extensive Phase III safety data for semaglutide and tirzepatide (Prescription Only Medicines with comprehensive clinical pharmacovigilance), through the well-characterised Phase IIb safety dataset for AOD-9604, the clinical diagnostic use data for GHRP-2, the selectivity comparison data for Ipamorelin, and the preclinical-only evidence base for BPC-157 and TB-500.

What all these compounds share is a research-grade characterisation requirement: published safety data applies to the pure, characterised compound — not to impure or misidentified material. Pure Grade Labs supplies HPLC-verified ≥99% purity compounds with batch-specific COAs precisely to ensure that researchers working with these molecules can rely on the compound identity and purity that makes their experimental results interpretable against the published literature.

None of the compounds discussed in this article are sold by Pure Grade Labs for human consumption, self-administration, or any therapeutic application. The safety profiles reported here are published research data — they are the starting point for scientific enquiry, not the basis for personal health decisions. For compounds that are Prescription Only Medicines (semaglutide, tirzepatide), clinical safety oversight by a licensed prescriber is a legal and medical requirement that cannot be replaced by reading published trial data.

References

  1. Sikiric P et al. (2018). Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 16(10):1523-1548. DOI: 10.2174/1570159X15666170619144410
  2. Sikiric P et al. (2018). Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design. 24(18):1990-2001. DOI: 10.2174/1381612824666180517104038
  3. Smart N et al. (2010). De novo cardiomyocytes from within the activated adult heart after injury. Nature. 474:640-644. DOI: 10.1038/nature10188
  4. Raun K et al. (1998). Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 139(5):552-561. DOI: 10.1530/eje.0.1390552
  5. Sackmann-Sala L et al. (2006). Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adults. Growth Hormone & IGF Research. 16(2):81-89. DOI: 10.1016/j.ghir.2006.02.001
  6. Heffernan MA et al. (2001). Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. International Journal of Obesity. 25(10):1442-1449. DOI: 10.1038/sj.ijo.0801740 [AOD-9604 preclinical]
  7. Marso SP et al. (2016). Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). New England Journal of Medicine. 375:1834-1844. DOI: 10.1056/NEJMoa1607141
  8. Frias JP et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine. 385:503-515. DOI: 10.1056/NEJMoa2107519
  9. Jastreboff AM et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 387:205-216. DOI: 10.1056/NEJMoa2206038
  10. Human Medicines Regulations 2012. SI 2012/1916. UK Statutory Instruments. legislation.gov.uk
Disclaimer: This article is for research and informational purposes only. All compounds described are sold by Pure Grade Labs for in vitro laboratory research purposes only and are not intended for human consumption, self-administration, or therapeutic use. Semaglutide and tirzepatide are Prescription Only Medicines in the UK and many other jurisdictions — they require a valid prescription from a licensed prescriber for clinical use. Safety profiles described in this article are summaries of published clinical trial and preclinical research data; they are not safety characterisations for individual human use and should not be treated as such. This content does not constitute medical advice. If you have questions about any medicine or supplement, consult a qualified healthcare professional.